Rejuvenation Medical Group of Canada uses MedMatrix AI Reporter to Streamline Reporting and Improve Operations

VANCOUVER, British Columbia, March 19, 2024 (GLOBE NEWSWIRE) — MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:1V7) today announced Rejuvenation medical group is using the commercial version of MedMatrix AI Reporter for centralized clinic operations reporting and dashboarding. The Company has a significant investment in the MedMatrix product suite.

The MedMatrix AI Reporter provides data reporting from the MedMatrix AI analytics platform, a complete dashboard of a clinic’s operations, and the MedMatrix AI Forecaster, which allows management to see how changes to the clinic’s resource matching, revenue models, market locations, and competition could improve business operations.

Rejuvenation is now using the MedMatrix AI Reporter across all 8 of its clinics spread across 3 provinces in Canada, comprising 21 dermatologists, 5 Mohs surgeons, 3 plastic surgeons, and 13 general practitioners specializing in dermatology. MedMatrix AI Reporter allows Rejuvenation to streamline its financial and operations reporting, by providing a centralized and complete view of operations across all clinics.

“We are extremely impressed with the reporting capabilities of the MedMatrix AI Reporter,” said Paul Kuzel, MD, Medical Director and Dermatologist at Rejuvenation medical group. “MedMatrix is already showing us where we have opportunities to improve our clinic, and we expect we will soon be using MedMatrix forecasting and AI engines to capture these opportunities.”

Rejuvenation is expected to use all 5 MedMatrix AI-enabled products as it works to improve resource utilization, expand its clinic footprints to enhance accessibility and grow its clinical trial recruitment programs across its sites.

“The partnership with Rejuvenation has been fantastic so far,” said Trevor Vieweg, CEO of MedBright. “We look forward to building on the success of MedMatrix AI Reporter with the launch of our 4 additional tools in Rejuvenation’s clinics in the near future.”

About MedBright AI Investments Inc.

MedBright AI is a capital allocator focused on investing in healthcare technology companies. The team at MedBright prides themselves on unparalleled access to opportunities, as well as structuring unique and advantageous investments. MedBright’s mission is to construct a portfolio of synergistic investments to generate superior returns for shareholders. MedBright will focus on significant near-term and midterm high-quality opportunities with strong return potentials while maintaining commitment to governance.

MedBright AI Investments Inc.
Trevor Vieweg, Chief Executive Officer
Email: investors@medbright.ai
Phone: (604) 602-0001

Cautionary Statement Regarding “Forward-Looking” Information 

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation, the anticipated benefits of the MedMatrix AI Reporter such as streamlined financial and operations reporting and improved business operations, including with respect to its use by Rejuvenation, the anticipated adoption of the rest of the MedMatrix product suite by Rejuvenation, and the Company’s plans to generate returns for its shareholders through its portfolio of investments, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” or occur.

Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that the MedMatrix AI Reporter will offer streamlined financial and operations reporting and improved business operations, including for Rejuvenation, that Rejuvenation will adopt the rest of the MedMatrix product suite, and that the Company will be able to generate returns for its shareholders. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that the MedMatrix AI Reporter will not offer streamlined financial and operations reporting and improved business operations, including for Rejuvenation, that Rejuvenation will not adopt the rest of the MedMatrix product suite, and the risk that the Company’s portfolio of investments will not generate returns for shareholders.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.